title: Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography.
authors.affiliation: From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.).
authors.forename: Fumiyuki
authors.initials: F
authors.lastname: Otsuka
authors.affiliation: From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.).
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Yahagi
authors.affiliation: From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.).
authors.forename: Elena
authors.initials: E
authors.lastname: Ladich
authors.affiliation: From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.).
authors.forename: Robert
authors.initials: R
authors.lastname: Kutys
authors.affiliation: From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.).
authors.forename: Russell
authors.initials: R
authors.lastname: Alexander
authors.affiliation: From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.).
authors.forename: David
authors.initials: D
authors.lastname: Fowler
authors.affiliation: From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.).
authors.forename: Renu
authors.initials: R
authors.lastname: Virmani
authors.affiliation: From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.). mjoner@cvpath.org.
authors.forename: Michael
authors.initials: M
authors.lastname: Joner
mesh_terms: D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000209:etiology; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D041623:Tomography, Optical Coherence / Q000379:methods*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: C489443:zotarolimus; D020123:Sirolimus